Citi Research: Maintains "Outperform" rating for SF INTRA-CITY (09699), net profit growth in 2024 in line with expectations.
CICC is optimistic about the company's third-party positioning and price competition in the custom delivery service industry.
CICC Ceres released a research report stating that SF INTRA-CITY (09699) announced its earnings for 2024, with net profit growth meeting the bank's expectations, and revenue growth exceeding expectations, with an annual growth rate of over 25%. The main drivers of revenue growth include the increase in penetration rate of key accounts (KA) and the continuous network integration with the company, driving growth in last-mile delivery volume. The bank is optimistic about the company's third-party positioning and price competition in the self-scheduled delivery service industry. The bank maintains its "outperform market" rating on the stock.
Related Articles
Ningbo Tianlong Electronics (603266.SH) General Manager Shen Chaohui plans to reduce his shareholding by no more than 320,000 shares.
TSUGAMI CHINA (01651) spent 2.479 million Hong Kong dollars to repurchase 80,000 shares on September 17th.
Jiangsu Hengrui Pharmaceuticals (01276) recently received acceptance of its application for market approval for the new indication of injection rituximab in combination with trastuzumab, and has been included in the priority review process.
Ningbo Tianlong Electronics (603266.SH) General Manager Shen Chaohui plans to reduce his shareholding by no more than 320,000 shares.
TSUGAMI CHINA (01651) spent 2.479 million Hong Kong dollars to repurchase 80,000 shares on September 17th.
Jiangsu Hengrui Pharmaceuticals (01276) recently received acceptance of its application for market approval for the new indication of injection rituximab in combination with trastuzumab, and has been included in the priority review process.
